If you would like to learn more about future focusIR related events and roundtables, please submit your details here

Less Ads, More Data, More Tools Register for FREE

Director/PDMR Shareholding

Today 14:30

RNS Number : 8469K
Haleon PLC
02 July 2026
 

 

Haleon plc: Director/PDMR Shareholding 

 

2 July 2026: Haleon plc (the "Company" or "Haleon") (LSE/NYSE: HLN) today announces notification and public disclosure in accordance with the requirements of The UK Market Abuse Regulation of Transactions by a Person Discharging Managerial Responsibilities ("PDMR").

 

This notification sets out the details of the vesting of a Haleon share award over ordinary shares made to a PDMR in October 2024 under the Haleon Performance Share Plan and the subsequent sale of ordinary shares to meet tax liabilities.

 

On 30 June 2026, Dawn Allen, Chief Financial Officer, received the vesting of an award of Haleon ordinary shares under the Haleon Performance Share Plan. Vesting included dividends accrued.

The award under the Performance Share Plan was conditional on continued employment and on the satisfaction of the performance conditions over the performance period ended on 31 December 2025 approved by the Remuneration Committee, which (after tax on the gross award) must be retained until the shareholding requirement is met, and in any event for Executive Directors two years after receipt.

Performance targets and levels of achievement are disclosed in the 2025 Annual Report and 20-F. The award is subject to malus and clawback provisions.

 

 

Details of the issuer or emission allowance market participant

 

a)

 

Name of the entity 

 

Haleon plc 

b)

 

LEI

 

549300PSB3WWEODCUP19 

 

 

Reason for the notification  

 

a)

 

Position/status

 

 

Chief Financial Officer

b)

 

Initial notification /Amendment to prior notifications

 

Initial Notification 

 

 

Details of the person discharging managerial responsibilities / person closely associated ("PCA")

a)

PDMR/PCA

PDMR

 

b)

 

Name 

 

Dawn Allen

 

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  

 

a)

 

Description of Instrument

Share

 

Identification code

GB00BMX86B70

 

b)

 

Nature of the transaction

 

 

Acquisition of Ordinary Shares in respect of the Haleon plc Performance Share Plan (Buyout award).

 

c)

 

Currency, Price(s) and Volume(s)

Price(s) 

Volume(s) 

Nil

283,193.151771

d)

 

Aggregated information

- Aggregated volume 

N/A

- Price 

e)

 

Date of the transaction

 

30 June 2026

f)

 

Place of the transaction

 

Outside a trading venue

 

 

 

Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted  

 

a)

 

Description of Instrument

Share

 

Identification code

GB00BMX86B70

 

b)

 

Nature of the transaction

 

 

Automatic disposal of Ordinary Shares resulting from Haleon plc Performance Share Plan (Buyout Award) vesting to cover tax liabilities.

 

c)

 

Currency, Price(s) and Volume(s)

Price(s) 

Volume(s) 

£3.523867

133,300.732432

d)

 

Aggregated information

- Aggregated volume 

N/A

- Price 

e)

 

Date of the transaction

 

30 June 2026

f)

 

Place of the transaction

 

London Stock Exchange (XLON) 

 

 

 

Amanda Mellor

Company Secretary

 

About Haleon

Haleon (LSE/NYSE: HLN) is a consumer company that is solely focused on better everyday health. Our people, our brands, our research, our investment and our innovation are aimed at improving the everyday health of consumers. Our product portfolio spans six major categories - Oral Health, Vitamins, Minerals and Supplements (VMS), Pain Relief, Respiratory Health, Digestive Health and Therapeutic Skin Health and Other. Our superior brands - such as Advil, Centrum, Otrivin, Panadol, parodontax, Polident, Sensodyne, Theraflu and Voltaren - are trusted by more than one billion consumers and are recommended by health professionals around the world.

 

For more information, please visit www.haleon.com

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
DSHBXGDRIBGDGLD

Related Shares

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Back to RNS